-
Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer
Advanced urothelial cancer (aUC) has seen remarkable progress in recent years with the emergence of antibody-drug conjugates (ADCs) targeting specific antigens. Trop-2, a cell surface antigen highly expressed in UC, has become a promising therapeutic target. Sacituzumab govitecan (SG), a next-generation Trop-2 ADC, received accelerated approval from the US FDA in April 2021 for treating…
-
Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation
The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer;…
-
Dr. Yao Zhu talks to Dr. Nguyen: Advances in Radiotherapy and Surgical Treatment of Prostate Cancer at ASCO-GU 2023
The 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU 2023) has concluded. During this conference, several studies related to early-stage/ localized prostate cancer radiotherapy or surgical treatment were presented as oral reports. Among them, the FORMULA-509 study presented by Dr. Paul L. Nguyen of the Dana-Farber Cancer Institute at Harvard Medical School…
-
AASLD Voice of China: Dr. Liang Peng’s Hepatitis B Research Highlights Safety and Efficacy of Antiviral Therapy for ‘Healthy’ Carriers
Editor’s Note: From November 10th to 14th, 2023, the annual international highlight event in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual…
-
Dr. Zhiren Chen: 3-year follow-up data from the START-FIT trial, showing an ORR of 67% for local advanced liver cancer patients
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. In recent years, with the continuous improvement of diagnosis and treatment, the misdiagnosis rate and mortality of early-stage HCC have greatly decreased. However, many patients are already at an advanced stage when liver cancer is detected, making curative treatment impossible. For these…
-
APPLE 2023 | Application of Arterial Therapy in Early Hepatocellular Carcinoma: Korean Experience
With the advancement and innovation in surgical techniques, interventions, radiofrequency ablation, and other treatment methods, there are increasing treatments for early hepatocellular carcinoma. Curative treatments, including liver resection, liver transplantation, interventional treatment, ablative treatment, and radiotherapy, have all achieved satisfactory results. However, how to effectively and minimally invasively treat early hepatocellular carcinoma and manage it…
-
Dr. Linda Wong: Adjuvant Therapy Could Usher in a New Paradigm for Early-Stage Liver Cancer Treatment
Early-stage liver cancer can be cured with radical surgery. However, tumor recurrence remains the primary challenge affecting patients’ long-term survival. Currently, the five-year recurrence rate for early-stage liver cancer post-surgery is about 60%. Addressing this challenge and improving long-term survival for these patients is a pressing clinical issue. From July 6th to 8th, 2023, the…
-
ESMO Hot Review | Prof. Ying Fan: DB-04 Study Shows Survival Benefit and Sustained Efficacy of T-DXd Treatment
Editor’s Note: The mid-term analysis results of the DESTINY-Breast04 (DB-04) study were striking, quickly influencing international guidelines such as NCCN and ESMO, and obtaining approvals for indications related to HER2…
Connecting Medical Expertise through Media